The question is good, but let me make a question back. 

From the oncological point of view, treatment of a cancer depends from its stage. The same is true for pancreatic cancer. So be a little bit more specific and provide us more details of the stage of pancreatic cancer you are intended to treat.... 

Please specify if you mean from a surgical or oncological point of view or from both.  Some areas of advances in early diagnosis and correct pre-operative staging (EUS) could also be considered some aspect of possible new trends.

i mean surgical management, and which kind of treatment can give maximum benefit to patient and can effect on survival rate of pancreatic cancer....thank you

Ablation.

Surgical standard care is:

Resectable cases: resection. 

Borderline cases: only venous involvement. resection on neoadjuvant chemo

Irresecable cases: chemo

Arterial resection is nowadays experimental not a standard of care

Artery first approach is more common everyday.

Several ways of making pancreatojejunostomy

See my article about tips and tricks in my RG profile (free in Pubmed)

Pancreatic ductal Adenocarcinoma (PDAC)

Evaluation operability  with scanner 3 phase and Echoendoscopy.

You can used the 3D reconstruction

If the pre-operative evaluation does not reveal local advanced pancreatic cancer or metastasis ( hepatic, lung, peritoneal ecc)    Surgery is the best treatment but R0 is required

The type of surgical resection depends of the tumor location

To concern the Cephalic Tumors

the resection of  Retro Portal lamina is mandatory to avoide R0 resection. 

"Artery-First " approch or

Augmented Reality (AR) consits in the fusion of synthetic computer-generated images (3D) and real-time patients images

The type of lymphadenectomy depends of the tumor location

See Tol J  Surgery 2014;156:591-600 consensus conference about definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma

For all the adjuvant chemiotherapy according staging

 If the pre-operative evaluation reveal local advanced pancreatic tumor without artery involvement :

• multimodality therapy: chemiotherapy first  (gemzar or folfirinox) 3 months after TC scanner evaluation if chemiotherapy response  SURGERY

If the pre-operative evalutaion reveal local advanced pancreatic tumor with artery involvement  the irreversible electroporation was proposed for palliation or classic  Chemiotherapy only

To concerns to cystic tumors or neuroendocrine tumors or rare cancers some other colleague can help!!!!!!!

I also  confirm that the article of  Dr. Josè Ramia (Anna Pallissera is the first Author), which has recently appeared in World Journal of Gastroenterology on September 15 2014, is a very interesting article and is a valuable tool for discussion about pancreatic cancer advances (surgical treatment of  tumours of the haed of the pancreas). I have also found interesting among many reviews available in literarture  "Current Practice in Pancreatic Surgery" by Philippe Bachellier  in the section "Liver and Pancreatic Diseases Management" Advances in Experimental Medicine and Biology by Springer ed.  Volume 574, 2006, pp 111-143 which is dedicated only to different  aspects of surgical techniques. For cystic tumors (PCN) and in particular for IPMN and MCN there is an international consensus published in Pancreatology 2012. Indications to recommend surgical resections in  only fit patients with BD-IPMN  If the margin is positive for high-grade dysplasia (the old so-called carcinoma in situ) .  The indications for resection of BD-IPMN are more conservative now.  Usually no surgery for lesions classified BD- IPMN of 3 cm  without clear “high-risk stigmata” can be observed without immediate resection. Surgical resection is only recommended for all surgically fit patients with MCN with  the evidence-based "worrisome features" based on multiple imaging modalities include cyst size >3 cm, thickening or hyperenhancement of the cyst walls, when Main Panc Duct (MPD) size is of 5–9 mm, when mural nodules are present or abrupt change in the MPD caliber (with distal pancreatic atrophy), and regional lymphadenopathy is evident.  For MCNs of

Folfirinox or (Gemcitabine + Abraxane) has been approved in the clinic for metastatic pancreatic cancer. the standard of care is still surgery for resectable PDAC. Folfirinox or Gem+Abraxane may have been studied on neoadjuvant setting but no clinical trail results are available yet. they are both very promising though, based on what I hear from the surgeons I work with.

Today surgery remain the only curative treatment for pancreatic cancer. 

For resectable cases (and the definition of resectable is very undefined), upfront surgery followed by adjuvant treatment seems to be the gold standard.

In my view in the resectable cases should be included even the ones with limited vein involvment. 

For locally advanced pancreatic cancer neo-adjuvant treatment followed by surgery seems to be the best option. 

Palliative chemotherapy is the treatment of metastatic patients.

Regarding the best "adjuvant or neoadjuvant" treatment, today, FOLFIRINOX seems to be associated with improved results. However, in my view, immunotherapy is also very promising. 

Pancreatic cancer can be divided in resectable, border-line resectable, locally advanced and metastatic disease. Surgery remains the only chance of cure but is not sufficient to ensure long survival. For resectable and border-line resectable disease surgery, followed by chemotherapy  and chemotherapy followed by surgery are the best options. The role of radiotherapy as adiuvant is not reccomanded. For locally advanced disease chemotherpy, with the possibility to add radiotherapy, is the preferred treatment. In the setting of metastatic disease only chemotherapy is administered or best supportive care. The preferred chemotherapy is Folfirinox. Remember that often, at the time of diagnosis  pancreatic cancer is already a metastatic disease with a high rate of distant and local relapse after optimal surgery.  

Agree with Dr. Chiaro. because of the high incidence of local recurrence and distant recurrence (metastasis) after surgery, the idea of pancreatic cancer as a systemic disease has been more popular, thus promoting clinical trials of up-front systemic chemotherapy with concurrent or sequential radiation therapy even in cases of resectable disease. Please ref to http://www.ncbi.nlm.nih.gov/pubmed/24563516

Dear Sally, unfortunately there are several definition of border-line resectable that, unfortunately are some time more surgical than oncologic definitions. What we really miss is a proper definition of locally advanced PC

Good discussion,all combinations mentioned have been in practice quite sometime. FOLFIRINOX is relatively new entrant.In our part of the country majority are locally advanced or unresectable.Even after a successful resection the outlook is poor.

Unfortunately there is no treatment modality to fulfill the criteria mentioned in your question: “… recent, modern and advanced…”. Surgery of PC is oldest treatment modality and the only one showing some (even far from desired) efficacy in terms of chance for cure. However it is clear from the early days of pancreatic surgery that there is also need of effective systemic treatment as PC usually is a systemic disease at least at the time of diagnosis. Talking about Chemo: Abraxane-containing regimens also showed intriguing response rates.

Radioablative therapy, basically excising metastatic lesions using radiation or some form of laparoscopy. This is generally, in my opinion based on my work, best suited for stage I-III tumors in the tail. I believe the whipple is still the procedure of choice for cases localized to the head.

In any event, following the procedure and once the patient is healthy they are treated with a concentrated focal dose of radiation which is more beneficial and compliments their improved state. They have several certified centers, studies and doctors who will share. I personally spoke with Johns Hopkins. I would suggest speaking with Dr. Cameron or Dr. Wolfgang. I studied it at length when my father was ill and find it works best after a course of Gemzar and Ambraxine (I can't remember how to spell it). In any event, my father was a prime candidate before being, in my opinion and others, wrongfully put on second line therapy. Unfortunately he died the day before his consultation. Be sure the read the ultrasounds and cat scans of the liver carefully. Differential diagnosis is generally benign nodules that lazy doctors assume are carcinogenic from the pancreas. For example, my father's tumor in the tail had shrunk with significant necrosis and the ablation was to get him better following the idiots at Vanderbilt's Xeloda and Flourocet (the name escapes me in my anger) despite my protests and work to get him out of there. Well we almost made it. I still plan on getting their licenses pulled as I don't believe in malpractice being that I come from a family of doctors. The only problem is they still will not release the medical records to me. I am sort of infamous there. Oh well... It is all about patient advocacy no matter what happens.